An assessment of the FDA’s breakthrough therapy designation program suggests the initiative is working as intended by the agency. A 30% approval rate out of 113 applications demonstrates clear differences from the FDA’s other review tracks, a study from the Tufts Center for the Study of Drug Development shows. The low acceptance rate “indicates that it’s meaningful to get the designation,” said Christopher-Paul Milne, the center’s research director.
